Actively Recruiting
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Led by Rambam Health Care Campus · Updated on 2026-02-03
30
Participants Needed
1
Research Sites
112 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
CONDITIONS
Official Title
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult oncology patients (18 years or older)
- Receiving apixaban or rivaroxaban for anticoagulation
- New or current metamizole users taking at least 1 gram three times daily for pain management
- Platelet count of at least 100 x 10�9/L
- ECOG performance status less than 3
- Provided informed consent
You will not qualify if you...
- History of allergic reaction to metamizole or direct oral anticoagulants
- Significant gastrointestinal disorders affecting absorption, including bowel obstruction, persistent diarrhea, or presence of a nasogastric tube
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rambam Health Care Campus
Haifa, Israel, 31096
Actively Recruiting
Research Team
L
Liat Rappaport
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here